Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q3 FY2018 Earnings Presentation
20 slides from Dr. Lal Pathlabs's earnings presentation, Feb 8, 2018
Slide 1: Dr. Lal PathLabs Limited Q3 & 9M FY18 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY18 Results Presentation February 08, 2018
Slide 2: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 3: Q3 FY18 Snapshot
Q3 FY18 Snapshot 26.6% Revenues INR 2,627 mn Samples Processed ~8.69 mn 20.2% EBITDA INR 566 mn Patients Tested ~3.82 mn 17.7% PAT INR 364 mn Total Employees ~4326 3
Slide 4: Kolkata Regional Reference Lab
Kolkata Regional Reference Lab Pilot testing operations commenced at the Regional Reference Laboratory at Kolkata Kolkata Reference Lab received final regulatory clearances and pilot testing operations have commenced. The World-class Lab will cater the demand from Northeast as well as Eastern region
Slide 5: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Performance Highlights 3 Financial Table 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Shareholding 10 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs 189 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,759 Patient Service diagnostic services Centers (PSCs) and 5,021 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralised IT panel
Slide 7: Key Performance Highlights
Key Performance Highlights Strong volume momentum achieved in Q3 expected to continue; captures growth in patient volumes and tests per patient. Initiatives to mitigate impact from GST, market pricing pressures and wage corrections supporting margins During Q3 FY18: • Recorded revenues of Rs. 2,627
Slide 8: Financial Table
Financial Table Growth Growth Particulars (Rs. mn) Q3 FY18 Q3 FY17 9M FY18 9M FY17 FY17 % % Total Revenue 2,627.0 2,074.6 26.6% 7,900.6 6,924.7 14.1% 9,123.8 Total Expenditure 2,061.0 1,603.6 5,901.0 5,048.3 6,749.2 EBITDA 566.0 471.1 20.2% 1,999.6 1,876.4 6.6% 2,374.6 RSU and stock based 29.9 15.6
Slide 9: Financial Highlights: Revenues
Financial Highlights Revenues All figures in Rs. mn 2,627 Q3 showed strong growth in Realisation per patient has 2,075 revenues at 26.6% to Rs. 2,627 stood stable at Rs. 688 owing million. Drivers during the quarter to price rationalisations were: undertaken during the year in • Expansion in pat
Slide 10: Financial Highlights: Normalised EBITDA
Financial Highlights All figures in Rs. mn Normalised EBITDA (after eliminating the impact of RSU and other stock based remuneration charges) Q3 normalised EBITDA (after Pressures from GST, correction 596 eliminating the impact of RSU and in minimum wages and market 487 other stock based remuner
Slide 11: Financial Highlights: PBT and PAT
Financial Highlights PBT All figures in Rs. mn 555 472 Q3 PBT stood at Rs. 555.0 million Q3 PAT stood at Rs. 364.0 in vs. Rs. 472.0 million in same million vs Rs 309.3 million in quarter last year Q3 previously Q3 FY17 Q3 FY18 1,880 1,993 9M PBT rose 6% to Rs. 1,993.4 9M PAT increased 6.7% t
Slide 12: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 1,759 189 1,559 164 172 1,340 5,668 146 4,967 5,021 1,064 4,225 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 No. of patients (mn) No. of samples (mn) 29.3 13.3 26.3 25.7 12.0 11.4 9.9 21.7 9.0 19.0 FY14 FY15 FY1
Slide 13: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “We have demonstrated a strong performance during the quarter backed by our focus on providing reliable and accurate diagnostic healthcare services to our customers through a robust ne
Slide 14: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 15: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 15
Slide 16: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 16
Slide 17: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 18: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Bharath Uppiliappan Shankha Banerjee Chief Financial Officer Chief Operating Officer Chief Growth
Slide 19: Shareholding as of 31st December, 2017
Shareholding as of 31st December, 2017 57.4% 12.5% 10.5% 0.3% 19.3% Promoter and Mutual FII DII Others Promoter Fund Group 19
Slide 20: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) For further information please contact: Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. Dilip Bidani It has an integrated nationwide network, where patients Dr. Lal PathLabs Limited and healthcare pro